Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Cooper Companies surged over 6.5% in premarket trading following a bombshell report that activist investor Jana Partners has taken a stake in the company and is pushing for sweeping strategic changes, including a high-profile merger of its contact lens unit with rival Bausch + Lomb.</li><li>The news, first reported by the Wall Street Journal, has sent shockwaves through the vision care industry.</li><li>Jana, known for catalyzing structural change across multiple sectors, is also urging Cooper to improve its capital allocation and returns, hinting at broader dissatisfaction with management’s operational strategy.</li></ul>

Cooper Companies surged over 6.5% in premarket trading following a bombshell report that activist investor Jana Partners has taken a stake in the company and is pushing for sweeping strategic changes, including a high-profile merger of its contact lens unit with rival Bausch + Lomb.The news, first reported by the Wall Street Journal, has sent shockwaves through the vision care industry.Jana, known for catalyzing structural change across multiple sectors, is also urging Cooper to improve its capital allocation and returns, hinting at broader dissatisfaction with management’s operational strategy.

Cooper Companies at a Crossroads: Activists Want In, Will the Board Give In?

The Cooper Companies Gets Activist Wake-Up Call: Jana Eyes Bausch + Lomb Tie-Up!

<ul><li>Cooper Companies recently reported its third-quarter financial results for the fiscal year 2025, showcasing a mixed performance.</li><li>Consolidated revenues increased by 5.7% year-over-year, reaching $1.06 billion, although organic growth was slightly muted at 2%.</li><li>Margins improved, contributing to a non-GAAP earnings growth of 15% to $1.10 per share.</li></ul>

Cooper Companies recently reported its third-quarter financial results for the fiscal year 2025, showcasing a mixed performance.Consolidated revenues increased by 5.7% year-over-year, reaching $1.06 billion, although organic growth was slightly muted at 2%.Margins improved, contributing to a non-GAAP earnings growth of 15% to $1.10 per share.

The Cooper Co Targets Japan Boom: MiSight Launch Set to Transform Growth!

<ul><li>Cooper Companies delivered a solid second quarter fiscal performance for 2025, exhibiting a 7% organic growth in consolidated revenues, driven primarily by robust expansions in its CooperVision and CooperSurgical segments.</li><li>CooperVision's revenue reached $670 million, showcasing a 7% organic growth, while CooperSurgical posted revenues of $333 million with similar organic growth.</li><li>The performance was notably buoyed by double-digit growth in key product lines such as daily silicone hydrogel lenses and the office and surgical portfolio.</li></ul>

Cooper Companies delivered a solid second quarter fiscal performance for 2025, exhibiting a 7% organic growth in consolidated revenues, driven primarily by robust expansions in its CooperVision and CooperSurgical segments.CooperVision's revenue reached $670 million, showcasing a 7% organic growth, while CooperSurgical posted revenues of $333 million with similar organic growth.The performance was notably buoyed by double-digit growth in key product lines such as daily silicone hydrogel lenses and the office and surgical portfolio.

<ul><li>The Cooper Companies, Inc., a global medical device company, started its fiscal year 2025 with a notable performance, achieving record Q1 revenues and earnings.</li><li>The company reported consolidated revenues of $965 million, which were up 4% year-over-year, and organic growth of 5%.</li><li>The financial performance was bolstered by a robust showing from both its business segments: CooperVision, which had a revenue increase of 4% (6% organically), and CooperSurgical, seeing a 3% uptick (2% organically).</li></ul>

The Cooper Companies, Inc., a global medical device company, started its fiscal year 2025 with a notable performance, achieving record Q1 revenues and earnings.The company reported consolidated revenues of $965 million, which were up 4% year-over-year, and organic growth of 5%.The financial performance was bolstered by a robust showing from both its business segments: CooperVision, which had a revenue increase of 4% (6% organically), and CooperSurgical, seeing a 3% uptick (2% organically).

The Cooper Companies: Strategic M&A & Innovation Indicating Firm Future Prospects In Surgical Healthcare Markets!

United States

The Cooper Companies, Inc. through its subsidiaries, develops, manufactures, and markets specialty healthcare products. The Company's products include contact lenses for the vision care market and diagnostic products, surgical instruments, and accessories for gynecologists and obstetricians.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cooper Cos (COO US)

Cooper Companies at a Crossroads: Activists Want In, Will the Board Give In?

Cooper Companies surged over 6.5% in premarket trading following a bombshell report that activist investor Jana Partners has taken a stake in the...

Baptista Research

The Cooper Companies Gets Activist Wake-Up Call: Jana Eyes Bausch + Lomb Tie-Up!

Cooper Companies surged over 6.5% in premarket trading following a bombshell report that activist investor Jana Partners has taken a stake in the...

Baptista Research

The Cooper Co Targets Japan Boom: MiSight Launch Set to Transform Growth!

Cooper Companies recently reported its third-quarter financial results for the fiscal year 2025, showcasing a mixed performance. Consolidated...

Baptista Research

Cooper Companies: Product Expansion

Cooper Companies delivered a solid second quarter fiscal performance for 2025, exhibiting a 7% organic growth in consolidated revenues, driven...

Baptista Research

The Cooper Companies: Strategic M&A & Innovation Indicating Firm Future Prospects In Surgical Healthcare Markets!

The Cooper Companies, Inc., a global medical device company, started its fiscal year 2025 with a notable performance, achieving record Q1 revenues...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)